ABSTRACT
Thrombosis related with antiphospholipid antibodies (aPL) has been described in almost every vessel in the human body. Thrombosis in Antiphospholipid Syndrome occurs in both venous and arterial blood vessels. The management of thrombotic events can be divided into acute, prophylactic, and thrombosis involving venous or arterial sites. C. G. Wathen et al. described a patient with aPL and recurrent venous thromboembolic episodes that were effectively prevented with long-term anticoagulation. The anticoagulant response to heparin varies widely among patients with thromboembolic disease. The low molecular weight heparins inhibit activated factor X to a greater degree than thrombin. Oral anticoagulants interfere with the formation of Gla-residues and therefore inhibit coagulation. Of the many drugs that inhibit platelet function, the effectiveness of acetylsalicylic acid as an antithrombotic agent has been studied most extensively. Other oral antiplatelet agents such as sulfinpyrazone, dipyridamole, and ticlopidine tested alone or in combination with aspirin gave similar results as trials with aspirin alone.
